326 related articles for article (PubMed ID: 26596782)
21. Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex.
Singh M; Popowicz GM; Krajewski M; Holak TA
Chembiochem; 2007 Jul; 8(11):1308-16. PubMed ID: 17582821
[TBL] [Abstract][Full Text] [Related]
22. Functional Roles of Bromodomain Proteins in Cancer.
Boyson SP; Gao C; Quinn K; Boyd J; Paculova H; Frietze S; Glass KC
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298819
[TBL] [Abstract][Full Text] [Related]
23. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
[TBL] [Abstract][Full Text] [Related]
24. Structure and acetyl-lysine recognition of the bromodomain.
Mujtaba S; Zeng L; Zhou MM
Oncogene; 2007 Aug; 26(37):5521-7. PubMed ID: 17694091
[TBL] [Abstract][Full Text] [Related]
25. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
Cheung KL; Kim C; Zhou MM
Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
[TBL] [Abstract][Full Text] [Related]
26. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
27. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
[TBL] [Abstract][Full Text] [Related]
28. A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.
Shin DG; Bayarsaihan D
Yale J Biol Med; 2017 Mar; 90(1):63-71. PubMed ID: 28356894
[TBL] [Abstract][Full Text] [Related]
29. Bromodomains: a new target class for drug development.
Cochran AG; Conery AR; Sims RJ
Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
[TBL] [Abstract][Full Text] [Related]
30. Bromodomain biology and drug discovery.
Zaware N; Zhou MM
Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
[TBL] [Abstract][Full Text] [Related]
31. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG
Structure; 2015 Oct; 23(10):1801-1814. PubMed ID: 26365797
[TBL] [Abstract][Full Text] [Related]
32. Biological function and histone recognition of family IV bromodomain-containing proteins.
Lloyd JT; Glass KC
J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
[TBL] [Abstract][Full Text] [Related]
33. Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.
Zaware N; Zhou MM
Curr Opin Chem Biol; 2017 Aug; 39():116-125. PubMed ID: 28689146
[TBL] [Abstract][Full Text] [Related]
34. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3.
Gamsjaeger R; Webb SR; Lamonica JM; Billin A; Blobel GA; Mackay JP
Mol Cell Biol; 2011 Jul; 31(13):2632-40. PubMed ID: 21555453
[TBL] [Abstract][Full Text] [Related]
35. Recent progress and structural analyses of domain-selective BET inhibitors.
Divakaran A; Harki DA; Pomerantz WCK
Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
[TBL] [Abstract][Full Text] [Related]
36. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
[TBL] [Abstract][Full Text] [Related]
37. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
38. Small molecules as tools to study the chemical epigenetics of lysine acetylation.
Schiedel M; Conway SJ
Curr Opin Chem Biol; 2018 Aug; 45():166-178. PubMed ID: 29958150
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
40. Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions.
Chandrasekaran R; Thompson M
Biochem Biophys Res Commun; 2007 Apr; 355(3):661-6. PubMed ID: 17320048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]